Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling WHK. et al, (2024), PLoS medicine, 21

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

Maitland K. et al, (2024), Wellcome Open Research, 8, 484 - 484

Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.

Kiguli S. et al, (2024), EClinicalMedicine, 72

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)

Maitland K. et al, (2024), Wellcome Open Research, 9, 281 - 281

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Kimathi D. et al, (2023), The Lancet. Infectious diseases, 23, 974 - 982

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

A global core outcome measurement set for snakebite clinical trials

Abouyannis M. et al, (2023), The Lancet Global Health, 11, e296 - e300

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.

Odera DO. et al, (2023), Science translational medicine, 15

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Sang S. et al, (2023), Wellcome open research, 8

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Hamaluba M. et al, (2023), Wellcome open research, 8

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial

Wamae K. et al, (2022), Wellcome Open Research, 7, 95 - 95

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response

Kapulu MC. et al, (2022), BMC Infectious Diseases, 22

A pragmatic randomized controlled trial of standard care versus steroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)

Lucinde R. et al, (2022), Wellcome Open Research, 7, 269 - 269

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.

Musasia FK. et al, (2022), Nature communications, 13

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

van der Pluijm RW. et al, (2022), The Lancet Infectious Diseases, 22, 765 - 766

Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis.

Marchello CS. et al, (2022), The Lancet. Infectious diseases, 22, 692 - 705

Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort study.

Nyamwaya DK. et al, (2022), PLoS medicine, 19

Targeted Amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial

Wamae K. et al, (2022), Wellcome Open Research, 7, 95 - 95

Load More

Include forthcoming?